• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

Improving Regulatory Pathways

The International Alliance of ALS/MND Associations encourages regulatory agencies around the world to develop a framework for global alignment in evaluating potential new therapies for people living with ALS/MND.

The Alliance believes that the ALS/MND community and all stakeholders will benefit from a more cooperative global approach to weighing the risks and benefits of new therapies, especially because drug development and clinical trials take place across many countries. People living with ALS/MND, wherever they live, have an extraordinary unmet need and want the fastest and widest possible access to therapies that may help them. Given how devastating ALS/MND is, this community cannot wait through excessive procedural delays caused by sequential reviews and hand-offs between regulators.

Pivotal (late-stage) clinical trials in ALS/MND are often conducted in several countries, and these global trials are increasingly important for testing the safety and effectiveness of ALS/MND drugs for approval. Drug development may benefit from more uniform global standards of treatment, which can lead to better trial designs.

The Alliance calls for a cooperative, harmonized pathway to approval that makes the evaluation of ALS/MND treatments more effective and faster, guided by the following principles.

Principles

  1. The perspectives, expertise, and experiences of people living with ALS/MND, their caregivers, and their health care providers, including their views on benefits and risks, should be at the core of clinical development and global regulatory review discussions.
  2. Regulators in each country and region align on regulatory review, with the purpose of driving outcomes.
  3. Regulators develop harmonized guidance and process pathways that encourage sponsors to engage with regulators before submitting applications for ALS/MND products, and to submit those applications to participating countries for concurrent review.
  4. Regulators establish ongoing, regular interaction to share information and engage with each other.
  5. The stakeholder community, working with regulators, develops objective measures of progress and uses them in reporting.
  6. Each regulatory authority identifies a Global Regulatory ALS/MND Lead.
  7. A global lead convener role is established, with responsibility that rotates among regulators.
  8. Regulators are transparent with all stakeholders in the ALS/MND community.

Read the full report

These principles were developed at a roundtable on October 5, 2021, that brought together people living with ALS/MND, caregivers, ALS/MND organizations, and industry representatives from more than a dozen countries.

Read the Regulatory Pathways Roundtable Report (PDF, 11 pages) →

Primary Sidebar

Advocacy

  • Advocacy Toolkit

  • Norm MacIsaac, Canada

    Norm MacIsaac, Canada

  • Ywan Dierick, Belgium

    Ywan Dierick, Belgium

  • Lee Millard, England

    Lee Millard, England

  • Yannick Richard, Canada

    Yannick Richard, Canada
    yannickrichard

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • Motoko Ogasawara, Japan

    Motoko Ogasawara, Japan

  • Anita Forte, USA

    Anita Forte, USA

  • Yessenia Hernandez Mendoza, Mexico

    Yessenia Hernandez Mendoza, Mexico

  • Erwin Coppejans, Belgium

    Erwin Coppejans, Belgium

  • Brian Lovell, Australia

    Brian Lovell, Australia

  • Calum Ferguson, Scotland

    Calum Ferguson, Scotland

  • Sam Hayden-Harler, UK

    Sam Hayden-Harler, UK

  • Carlos Gomez Matallanas, Spain

    Carlos Gomez Matallanas, Spain

  • Chih Ching Darren Wong, Malaysia

    Chih Ching Darren Wong, Malaysia

  • Lineke Veenstra, Netherlands

    Lineke Veenstra, Netherlands

  • Susan Keldani, USA

    Susan Keldani, USA

  • Murat Morali, Turkey

    Murat Morali, Turkey

  • Mahmood Anwar, UK

    Mahmood Anwar, UK

  • PALS and CALS, Singapore

    PALS and CALS, Singapore

  • Jorge Luis Fernández Romero, Mexico

    Jorge Luis Fernández Romero, Mexico

  • Kirsten Harley, Australia

    Kirsten Harley, Australia

  • Ali Var, Turkey

    Ali Var, Turkey

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • Roy Taylor, Ireland

    Roy Taylor, Ireland
    roy

  • Luis Antonio Pimenta Lima, Brazil

    Luis Antonio Pimenta Lima, Brazil

  • Monica Soriano, Argentina

    Monica Soriano, Argentina

  • Lucy Lintott, Scotland

    Lucy Lintott, Scotland

  • Emilienne Verhaegen, Belgium

    Emilienne Verhaegen, Belgium

  • Maurice LeClerc, Canada

    Maurice LeClerc, Canada

  • Hiroshi Matsuyama, Japan

    Hiroshi Matsuyama, Japan

  • Animesh Kumar, India

    Animesh Kumar, India

  • Aida Trzmiel de Guterman, Argentina

    Aida Trzmiel de Guterman, Argentina

  • Mikey Stone, ALS

    Mikey Stone, ALS

  • Oliver Juenke, Germany

    Oliver Juenke, Germany

  • Andrietta, Italy

    Andrietta, Italy
    Andrietta

  • H. Todd Kelly, USA

    H. Todd Kelly, USA

  • Dawn Morton, Scotland

    Dawn Morton, Scotland

  • Fabio Correia, Brazil

    Fabio Correia, Brazil

  • Claudette Sturk, Canada

    Claudette Sturk, Canada
    Picture2

  • Jette Odgaard Villemoes, Denmark

    Jette Odgaard Villemoes, Denmark

  • Elkin Gaviria, Colombia

    Elkin Gaviria, Colombia

  • Manuel Arn, Switzerland

    Manuel Arn, Switzerland

  • Fernando Ocampo Cardona, Colombia

    Fernando Ocampo Cardona, Colombia

  • Vincent Bourque, Canada

    Vincent Bourque, Canada
    vincent_bourque

  • Purningam Jacob, India

    Purningam Jacob, India

  • Carlos Alberto Báez Murillo, Colombia

    Carlos Alberto Báez Murillo, Colombia

  • Len Johnrose, England

    Len Johnrose, England

  • Alfredo Santos, Colombia

    Alfredo Santos, Colombia

  • Mauricio Dorin, Argentina

    Mauricio Dorin, Argentina

  • Diana Fernandez, Argentina

    Diana Fernandez, Argentina

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login